81363-76-0

Basic information

• Product Name: Isopropylsulfonamide
• Synonyms: propane-2-sulfonamide;Isopropylsulfonamide;IsopropylsulfonamidePropane-2-sulfonamide;Propane-2-sulphonamide, 2-Sulphamoylpropane;2-Propanesulfonamide
• CAS NO: 81363-76-0
• Molecular Formula: C₃H₉NO₂S
• Molecular Weight: 123.17
• Product Categories: CHIRAL CHEMICALS
• Mol File: 81363-76-0.mol

Chemical Properties

• Melting Point: 61-65 °C(Solv: chloroform (67-66-3); carbon tetrachloride (56-23-5))
• Boiling Point: 216.5 °C at 760 mmHg
• Flash Point: 84.7 °C
• Appearance: /
• Density: 1.194 g/cm³
• Vapor Pressure: 0.14mmHg at 25°C
• Refractive Index: 1.461
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.69±0.60(Predicted)
• CAS DataBase Reference: Isopropylsulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: Isopropylsulfonamide(81363-76-0)
• EPA Substance Registry System: Isopropylsulfonamide(81363-76-0)

Safety Data

• Hazardous Substances Data: 81363-76-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C3H9NO2S/c1-3(2)7(4,5)6/h3H,1-2H3,(H2,4,5,6)

Upstream product

• 10147-37-2 Isopropylsulfonyl chloride 
• 149944-33-2 N-benzyl-propane-2-sulfonamide 
• 149220-47-3 C₇H₁₇NO₂S 
• 7664-41-7 ammonia 
• 807329-97-1 TurboGrignard 
• 19955-41-0 isopropanesulfinamide 
• 27719-14-8 ethylidene isopropylamine 
• 256532-43-1 N-(tert-butoxycarbonyl) isopropylsulfonamide 

Downstream Products

• 126502-39-4 N-{1-(3-Cyano-benzyl)-3-[2-methoxy-4-(propane-2-sulfonylaminocarbonyl)-benzyl]-1H-indol-5-yl}-2-cyclopentyl-acetamide 
• 104448-66-0 2-Ethyl-hexanoic acid {1-[2-methoxy-4-(propane-2-sulfonylaminocarbonyl)-benzyl]-1H-indol-6-yl}-amide 
• 335-05-7 Trifluoromethanesulfonyl fluoride 
• 354-87-0 pentafluoroethanesulfonyl fluoride 
• 423-40-5 1-perfluoropropanesulfonyl fluoride 
• 14856-91-8 perfluoroisopropylsulfonyl fluoride 
• 1026682-12-1 propane-2-sulfonic acid (7-{3,5-bis-(tert-butyl-dimethyl-silanyloxy)-2-[3-(tert-butyl-dimethyl-silanyloxy)-4-phenylsulfanyl-butyl]-cyclopentyl}-heptanoyl)-amide 
• 145878-41-7 1-(Isopropylsulfonylaminocarbonyl)-3-nitro-benzene 
• 26118-67-2 isopropylsulfamoyl chloride 
• 1059701-53-9 (1aR,12bS)-8-cyclohexyl-N-(isopropylsulfonyl)-11-methoxy-1a-((5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 945686-05-5 methyl 13-cyclohexyl-10-((isopropylsulfonyl)carbamoyl)-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6-carboxylate 
• 1059700-13-8 (1aR,12bS)-8-cyclohexyl-N-(isopropylsulfonyl)-11-methoxy-1a-((5-(2-methoxyethyl)-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 

Relevant articles and documents

Development of succinimide-based inhibitors for the mitochondrial rhomboid protease PARL

While the biochemistry of rhomboid proteases has been extensively studied since their discovery two decades ago, efforts to define the physiological roles of these enzymes are ongoing and would benefit from chemical probes that can be used to manipulate the functions of these proteins in their native settings. Here, we describe the use of activity-based protein profiling (ABPP) technology to conduct a targeted screen for small-molecule inhibitors of the mitochondrial rhomboid protease PARL, which plays a critical role in regulating mitophagy and cell death. We synthesized a series of succinimide-containing sulfonyl esters and sulfonamides and discovered that these compounds serve as inhibitors of PARL with the most potent sulfonamides having submicromolar affinity for the enzyme. A counterscreen against the bacterial rhomboid protease GlpG demonstrates that several of these compounds display selectivity for PARL over GlpG by as much as two orders of magnitude. Both the sulfonyl ester and sulfonamide scaffolds exhibit reversible binding and are able to engage PARL in mammalian cells. Collectively, our findings provide encouraging precedent for the development of PARL-selective inhibitors and establish N-[(arylsulfonyl)oxy]succinimides and N-arylsulfonylsuccinimides as new molecular scaffolds for inhibiting members of the rhomboid protease family.

Primary Sulfonamide Synthesis Using the Sulfinylamine Reagent N-Sulfinyl- O-(tert-butyl)hydroxylamine, t-BuONSO

Sulfonamides have played a defining role in the history of drug development and continue to be prevalent today. In particular, primary sulfonamides are common in marketed drugs. Here we describe the direct synthesis of these valuable compounds from organometallic reagents and a novel sulfinylamine reagent, t-BuONSO. A variety of (hetero)aryl and alkyl Grignard and organolithium reagents perform well in the reaction, providing primary sulfonamides in good to excellent yields in a convenient one-step process.

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS

The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV

BENZIMIDAZOLONE CHYMASE INHIBITORS

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.

Mild and general method for the synthesis of sulfonamides

Reaction of methyl sulfinates with lithium amides followed by 3-chloroperoxybenzoic acid oxidation of the resulting sulfinamides provides primary, secondary, and tertiary alkane-, arene-and heteroarenesulfonamides in high yields. This constitutes a mild and facile experimental protocol that avoids the use of hazardous, unstable, or volatile reagents and does not affect the configurational stability of the amines. Georg Thieme Verlag Stuttgart.

QUINOXALINE COMPOUNDS AND USE THEREOF

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

PYRIDAZINONE COMPOUNDS

The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases

An isovaleramide analog having at least one of an increased potency, an increased half-life, and an increased stability compared to isovaleramide. The isovaleramide analog is a cyclic analog or a noncyclic analog. The isovaleramide analog is formulated into a pharmaceutical composition. A method of treating a central nervous system condition or disease is also disclosed. The method comprises administering an isovaleramide analog to a patient suffering from the central nervous system condition or disease.